

Antoine N Saliba

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/64468/publications.pdf>

Version: 2024-02-01

33
papers

391
citations

1040056

9
h-index

839539

18
g-index

33
all docs

33
docs citations

33
times ranked

546
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. American Journal of Hematology, 2022, 97, .	4.1	24
2	Immunotherapy-associated Autoimmune Hemolytic Anemia. Hematology/Oncology Clinics of North America, 2022, 36, 365-380.	2.2	4
3	Racial disparities in patients with TP53 mutated acute myeloid leukemia.. Journal of Clinical Oncology, 2022, 40, e19007-e19007.	1.6	0
4	A land in agony: COVID-19, economic collapse, political corruption, and a deadly blast. American Journal of Hematology, 2021, 96, E1-E2.	4.1	9
5	Metastatic Colon Cancer Presenting With Immune-mediated Necrotizing Myopathy. Clinical Colorectal Cancer, 2021, 20, e71-e73.	2.3	1
6	Does race play a role in complications and outcomes of Philadelphia chromosome-negative myeloproliferative neoplasms?. Hematology/ Oncology and Stem Cell Therapy, 2021, , .	0.9	2
7	Outcomes of cardiac resynchronization therapy in patients with chemotherapy-induced cardiomyopathy. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 625-632.	1.2	4
8	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	6.2	11
9	CSF3R T618I mutant chronic myelomonocytic leukemia (CMML) defines a proliferative CMML subtype enriched in ASXL1 mutations with adverse outcomes. Blood Cancer Journal, 2021, 11, 54.	6.2	5
10	Innovation in Resident Core Oncology Education: Switching from an Inpatient Ward Rotation to a Hybrid Model of Inpatient Consultations and Outpatient Clinics. Journal of Cancer Education, 2021, , 1.	1.3	0
11	Insurance status and survival in diffuse large B-cell lymphoma: A National Cancer Database study before and after the Affordable Care Act.. Journal of Clinical Oncology, 2021, 39, 6539-6539.	1.6	0
12	Immune-related hematologic adverse events in the context of immune checkpoint inhibitor therapy. American Journal of Hematology, 2021, 96, E362-E367.	4.1	4
13	The Lebanese healthcare sector: The point of exsanguination. American Journal of Hematology, 2021, 96, E403-E404.	4.1	1
14	Outcomes of venetoclax-based therapy in chronic phase and blast transformed chronic myelomonocytic leukemia. American Journal of Hematology, 2021, 96, E433-E436.	4.1	10
15	Association of a Remote Patient Monitoring (RPM) Program With Reduced Hospitalizations in Cancer Patients With COVID-19. JCO Oncology Practice, 2021, 17, e1293-e1302.	2.9	18
16	Outcomes of COVID-19 in Patients With Cancer: A Closer Look at Pre-Emptive Routine Screening Strategies. JCO Oncology Practice, 2021, 17, e1382-e1393.	2.9	5
17	Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia. , 2021, 4, 125-142.		26
18	Influence of Treatment Facility Type and Annual Patient Volume on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. Blood, 2021, 138, 1348-1348.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Impact of Diagnosis-to-Treatment Interval on Overall Survival in Patients with Mantle Cell Lymphoma: A National Cancer Database Analysis. <i>Blood</i> , 2021, 138, 3549-3549.	1.4	0
20	PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword. <i>Cancers</i> , 2021, 13, 6385.	3.7	19
21	Thalassemia in the emergency department: special considerations for a rare disease. <i>Annals of Hematology</i> , 2020, 99, 1967-1977.	1.8	9
22	Aetiology and outcomes of secondary myelofibrosis occurring in the context of inherited platelet disorders: A single institutional study of four patients. <i>British Journal of Haematology</i> , 2020, 190, e316-e320.	2.5	9
23	Immune-Related Hematologic Adverse Events in the Context of Checkpoint Inhibitors. <i>Blood</i> , 2020, 136, 31-32.	1.4	1
24	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. <i>Blood</i> , 2020, 136, 44-44.	1.4	0
25	Disparities in the risk of septic events in patients undergoing splenectomy for hematological malignancies (Dâ€ROSEâ€PUSH): A study based on ACSâ€NSQIP database. <i>American Journal of Hematology</i> , 2019, 94, E205-E207.	4.1	0
26	Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials. <i>Leukemia Research</i> , 2019, 77, 30-33.	0.8	13
27	Assessment and study of knowledge and practice across different settings in Lebanon based on the recommendations of the American Society of Hematology <i>Choosing Wisely</i> campaign (ASKâ€PADS) Tj ETQq1.1 0.784614 rgB	1.1	0
28	Serum ferritin values between 300 and 800 ng/mL in nontransfusionâ€dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable. <i>American Journal of Hematology</i> , 2017, 92, E35-E37.	4.1	13
29	Safety and pharmacokinetics of the oral iron chelator SPâ€420 in Î²â€thalassemia. <i>American Journal of Hematology</i> , 2017, 92, 1356-1361.	4.1	10
30	Causes of hospital admission in Î²â€thalassemia (CHAT) in Lebanon from 1995 to 2015: A pilot retrospective study from a tertiary care center. <i>American Journal of Hematology</i> , 2017, 92, E652-E653.	4.1	1
31	Iron overload in thalassemia: different organs at different rates. <i>Hematology American Society of Hematology Education Program</i> , 2017, 2017, 265-271.	2.5	167
32	Morbidities in nonâ€transfusionâ€dependent thalassemia. <i>Annals of the New York Academy of Sciences</i> , 2016, 1368, 82-94.	3.8	20
33	Deferasirox in thalassemia patients with endâ€stage renal disease. <i>American Journal of Hematology</i> , 2016, 91, E456-7.	4.1	5